

09/720952

Page 1

11/27/2001

115

STM

## Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID: ssspta1626qms

**PASSWORD:**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS	3	Feb 06 Engineering Information Encompass files have new names
NEWS	4	Feb 16 TOXLINE no longer being updated
NEWS	5	Apr 23 Search Derwent WPINDEX by chemical structure
NEWS	6	Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS	7	May 07 DGENE Reload
NEWS	8	Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS	9	JUL 13 New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS	10	Aug 23 In-process records and more frequent updates now in MEDLINE
NEWS	11	Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS	12	Aug 23 Adis Newsletters (ADISNEWS) now available on STN
NEWS	13	Sep 17 IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	14	Oct 09 Korean abstracts now included in Derwent World Patents Index
NEWS	15	Oct 09 Number of Derwent World Patents Index updates increased
NEWS	16	Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	17	Oct 22 Over 1 million reactions added to CASREACT
NEWS	18	Oct 22 DGENE GETSIM has been improved
NEWS	19	Oct 29 AAASD no longer available
NEWS	20	Nov 19 New Search Capabilities USPATFULL and USPAT2
NEWS	21	Nov 19 TOXCENTER(SM) - new toxicology file now available on STN
NEWS EXPRESS		August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

09/720952

Page 2

11/27/2001

FILE 'HOME' ENTERED AT 18:07:13 ON 27 NOV 2001

=> file registry			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	0.15	0.15	

FILE 'REGISTRY' ENTERED AT 18:07:25 ON 27 NOV 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 26 NOV 2001 HIGHEST RN 371913-98-3  
DICTIONARY FILE UPDATES: 26 NOV 2001 HIGHEST RN 371913-98-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
Uploading 09720952.str

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

Golam Shameem

09/720952

Page 3

11/27/2001

=> s 11  
SAMPLE SEARCH INITIATED 18:08:01 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 200 TO 800  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full  
FULL SEARCH INITIATED 18:08:11 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 499 TO ITERATE

100.0% PROCESSED 499 ITERATIONS  
SEARCH TIME: 00.00.01


0 ANSWERS

L3 0 SEA SSS FUL L1

=>  
Uploading 09720952a.str

L4 STRUCTURE UPLOADED

=> d 14  
L4 HAS NO ANSWERS  
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 14  
SAMPLE SEARCH INITIATED 18:10:22 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 344 TO ITERATE

100.0% PROCESSED 344 ITERATIONS

8 ANSWERS

Golam Shameem

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5768 TO 7992  
PROJECTED ANSWERS: 8 TO 329

L5 8 SEA SSS SAM L4

=> s 14 sss full  
FULL SEARCH INITIATED 18:10:40 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 7156 TO ITERATE

100.0% PROCESSED 7156 ITERATIONS  
SEARCH TIME: 00.00.01

148 ANSWERS

L6 148 SEA SSS FUL L4

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
268.36 268.51

FILE 'CAPLUS' ENTERED AT 18:10:51 ON 27 NOV 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 27 Nov 2001 VOL 135 ISS 23  
FILE LAST UPDATED: 26 Nov 2001 (20011126/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> d his

Golam Shameem

(FILE 'HOME' ENTERED AT 18:07:13 ON 27 NOV 2001)

FILE 'REGISTRY' ENTERED AT 18:07:25 ON 27 NOV 2001

L1                   STRUCTURE UPLOADED  
L2                   0 S L1  
L3                   0 S L1 SSS FULL  
L4                   STRUCTURE UPLOADED  
L5                   8 S L4  
L6                   148 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:10:51 ON 27 NOV 2001

=> s 16  
L7                   69 L6  
=> s 16/proc  
69 L6  
3056865 PROC/RL  
L8                   7 L6/PROC  
(L6 (L) PROC/RL)

=&gt; d 17 ibib abs hitstr tot


L7   ANSWER 1 OF 69 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER:       2001:753814 CAPLUS  
DOCUMENT NUMBER:       135:287598  
TITLE:                  Pravastatin manufacture with Microtetrasporea  
INVENTOR(S):           Okabe, Mitsuyasu  
PATENT ASSIGNEE(S):    Mercian Corp., Japan  
SOURCE:                Jpn. Kokai Tokkyo Koho, 6 pp.  
CODEN:                JKXXAF  
DOCUMENT TYPE:        Patent  
LANGUAGE:              Japanese  
FAMILY ACC. NUM. COUNT:    1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001286293	A2	20011016	JP 2000-104278	20000406
AB	Pravastatin (I), an hypolipemic, is manufd. with Microtetrasporea such as M. recticatena from mevastatin or its open ring form. The I may be a lactone form or a salt. The physiol. and morphol. characteristics of the microorganism were also given.			
IT	85956-22-5P, Pravastatin lactone RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (pravastatin manuf. with Microtetrasporea)			
RN	85956-22-5 CAPLUS			
CN	Butanoic acid, 2-methyl-, (1S,3S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3-hydroxy-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.

[1S-[1.alpha.(S\*),3.alpha.,7.beta.,8.beta.(2S\*,4S\*),8a.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 18:07:13 ON 27 NOV 2001)

FILE 'REGISTRY' ENTERED AT 18:07:25 ON 27 NOV 2001


L1                   STRUCTURE UPLOADED  
L2                   0 S L1  
L3                   0 S L1 SSS FULL  
L4                   STRUCTURE UPLOADED  
L5                   8 S L4  
L6                   148 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:10:51 ON 27 NOV 2001

L7                   69 S L6  
L8                   7 S L6/PROC

=> d 18 ibib abs hitstr tot

L8   ANSWER 1 OF 7 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 2001:2410 CAPLUS  
DOCUMENT NUMBER: 134:193253  
TITLE: Oxidation of HMG-CoA reductase inhibitors by  
        tert-butoxyl and 1,1-diphenyl-2-picrylhydrazyl  
        radicals: model reactions for predicting oxidatively  
        sensitive compounds during preformulation  
AUTHOR(S): Karki, Shyam B.; Treemanekarn, Varaporn; Kaufman,  
            Michael J.  
CORPORATE SOURCE: Pharmaceutical Research and Development Department,  
                      Merck Research Laboratories, West Point, PA, 19486,  
                      USA  
SOURCE: J. Pharm. Sci. (2000), 89(12), 1518-1524  
        CODEN: JPMSAE; ISSN: 0022-3549  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



**AB** Hydrogen atom abstraction rate consts. for the reaction of tert-butoxyl and 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical with the HMG-CoA reductase inhibitors lovastatin (I, R<sub>1</sub> = H, R<sub>2</sub> = .beta.-Me, R<sub>3</sub> = .alpha.-Me), simvastatin (I, R<sub>1</sub> = Me, R<sub>2</sub> = Me, R<sub>3</sub> = .alpha.-Me), and statins I (I, R<sub>1</sub> = H, R<sub>2</sub> = .beta.-Me, R<sub>3</sub> = H), II (I, R<sub>1</sub> = H, R<sub>2</sub> = .beta.-Me, R<sub>3</sub> = .beta.-CH<sub>2</sub>OH), III (II), and IV (I, R<sub>1</sub> = Me, R<sub>2</sub> = Me, R<sub>3</sub> = .beta.-OH) were measured. This series of diene-contg. drugs is known to be prone to oxidn. The tert-butoxyl radical was generated by the thermolysis of di-tert-butylperoxyoxalate at 40.degree.C. A competitive kinetic method was used to det. the relative rate of hydrogen atom abstraction by tert-butoxyl radical to .beta.-scission. The abs. rate consts. were calcd. using the exptl. detd. product ratios of t-butanol to acetone and the known rate of .beta.-scission of tert-butoxyl radical. The rate consts. for the reaction with DPPH radical were measured spectrophotometrically by monitoring the loss of DPPH radical as a function of substrate concn. The rate consts. correlate well with the structure of the mols. studied. These kinetic techniques allow for oxidatively sensitive compds. to be identified early in the drug development cycle. The tert-butoxyl radical, a strong hydrogen atom abstractor, is representative of the hydroxyl (.cntdot.OH) and alkoxy (.cntdot.OR) radicals; in contrast the DPPH radical, a much weaker radical, is a good kinetic model for hydroperoxyl (.cntdot.OOH) and peroxy (.cntdot.OOR) radicals. These kinetic methods can be used to quant. assess the lability of drug candidates towards reaction with oxygen-centered radicals at an early stage of development and facilitate the design of inhibiting strategies.

**IT** 327037-01-4, Statin IV


RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); **PROC (Process)**

(oxidn. of HMG-CoA reductase inhibitors by tert-butoxyl and 1,1-diphenyl-2-picrylhydrazyl radicals)

**RN** 327037-01-4 CAPLUS

**CN** Butanoic acid, 2,2-dimethyl-, (1S,3S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3-hydroxy-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

16

REFERENCE(S):

- (1) Bartlett, P; J Am Chem Soc 1960, V82, P1762 CAPLUS
  - (3) Cuthbertson, M; Aust J Chem 1983, V36, P1957 CAPLUS
  - (4) Ellison, D; Analytical profiles of drug substances and excipients 1993, V22, P359 CAPLUS
  - (5) Kaufman, M; Pharm Res 1990, V7, P289 CAPLUS
  - (6) Kennedy, B; Can J Chem 1966, V44, P2381 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:165425 CAPLUS

DOCUMENT NUMBER: 133:53181

TITLE:

Effect of multiple cilostazol doses on single-dose lovastatin pharmacokinetics in healthy volunteers

Bramer, Steven L.; Brisson, Jerry; Corey, Alfred E.; Mallikaarjun, Suresh

CORPORATE SOURCE: Otsuka America Pharmaceutical, Inc., Rockville, MD, USA

SOURCE: Clin. Pharmacokinet. (1999), 37 (Suppl. 2), 69-77  
CODEN: CPKNDH; ISSN: 0312-5963

PUBLISHER: Adis International Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Volunteers received single oral doses of 80 mg lovastatin on days 1, 7 and 9, as well as 100 mg oral cilostazol twice daily on days 2-8, followed by a single oral 150-mg cilostazol dose on day 9. Pharmacokinetic parameters were calcd. by using plasma concns. of lovastatin and its .beta.-hydroxy metabolite and of cilostazol and its metabolites. Differences in the pharmacokinetics of each drug when given alone or in combination were assessed by anal. of variance. The max. obsd. plasma concn. (Cmax) of lovastatin or its metabolite did not differ significantly when lovastatin was given alone and when it was given with 100 mg cilostazol. The mean ratios of the area under the plasma concn.-time curve from zero to the time of the last measurable concn. (AUCt) for lovastatin coadministered with 100 mg cilostazol to that with lovastatin given alone were 1.6 for lovastatin and 1.7 for its metabolite. With 150 mg cilostazol, lovastatin Cmax did not change, whereas Cmax of the metabolite increased 2.2-fold. The mean AUCt ratios for lovastatin given with 150 mg cilostazol/lovastatin given alone were 1.6 and 2.0 for lovastatin and its metabolite, resp. All the increases in lovastatin and metabolite AUC were significant, except for the 1.6-fold increase in lovastatin AUC with 150 mg cilostazol. Maximum steady-state plasma drug concn. and AUC during a

dosage (AUCt) of 100 mg cilostazol twice daily decreased 14 and 15%, resp., upon lovastatin coadministration. Thus, exposure to lovastatin and its metabolite is increased by only ~2-fold when cilostazol is coadministered, which is considerably less than that obsd. for potent cytochrome P 450 3A inhibitors such as itraconazole and grapefruit juice. Absorption of cilostazol decreased approx. 15% when it was given with lovastatin. No dosage adjustments are necessary for cilostazol when coadministered with lovastatin, whereas lovastatin dose redns. may be needed when the 2 drugs are given together.


IT 125638-71-3

RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)  
(multiple cilostazol doses effect on single-dose lovastatin pharmacokinetics in humans in relation to formation of)

RN 125638-71-3 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3-hydroxy-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

8

REFERENCE(S) :

- (1) Abbas, R; To be published in Hum Exp Toxicol
  - (2) Jusko, W; Applied pharmacokinetics -- principles of therapeutic drug monitoring 1986
  - (3) Kantola, T; Clin Pharmacol Ther 1998, V63(4), P397 CAPLUS
  - (6) Neuvonen, P; Clin Pharmacol Ther 1996, V60(1), P54 CAPLUS
  - (8) Transon, C; Eur J Clin Pharmacol 1996, V50(3), P209 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:632712 CAPLUS

DOCUMENT NUMBER: 132:93

TITLE:

Small intestinal metabolism of the  
3-hydroxy-3-methylglutaryl-coenzyme A reductase  
inhibitor lovastatin and comparison with pravastatin  
Jacobsen, Wolfgang; Kirchner, Gabriele; Hallensleben,  
Katrín; Mancinelli, Laviero; Deters, Michael;  
Hackbarth, Ingelore; Baner, Karen; Benet, Leslie Z.;  
Sewing, Karl-Friedrich; Christians, Uwe

AUTHOR(S):

CORPORATE SOURCE: Department of Biopharmaceutical Sciences, School of Pharmacy, University of California, San Francisco, CA, USA

SOURCE: J. Pharmacol. Exp. Ther. (1999), 291(1), 131-139  
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English


AB We compared the intestinal metab. of the structurally related 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in vitro. Human small intestinal microsomes metabolized lovastatin to its major metabolites 6'.beta.-hydroxy (apparent Km = 11.2.+-.3.3 .mu.M) and 6'-exomethylene (apparent Km = 22.7.+-.9.0 .mu.M) lovastatin. The apparent Km values were similar for lovastatin metab. by human liver microsomes. 6'.beta.-Hydroxylovastatin formation by pig small intestinal microsomes was inhibited with the following inhibition Ki values: cyclosporine, 3.3.+-.1.2 .mu.M; ketoconazole, 0.4.+-.0.1 .mu.M; and troleandomycin, 0.8.+-.0.9 .mu.M. Ki values for 6'-exomethylene lovastatin were similar. Incubation of pravastatin with human small intestinal microsomes resulted in the generation of 3'.alpha.,5'.beta.,6'.beta.-trihydroxypravastatin (apparent Km = 4560.+-.1410 .mu.M) and hydroxypravastatin (apparent Km = 5290.+-.1740 .mu.M). In addn., as in the liver, pravastatin was metabolized in the small intestine by sulfation and subsequent degrdn. to its main metabolite 3'.alpha.-iso-pravastatin. It was concluded that lovastatin is metabolized by cytochrome P 450 3A enzymes in the small intestine. Compared with lovastatin, the cytochrome P 450-dependent intestinal intrinsic clearance of pravastatin was >5000-fold lower and cannot be expected to significantly affect its oral bioavailability or to be a significant site of drug interactions.

IT 125638-71-3, 6'.beta.-Hydroxylovastatin  
RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)  
(small intestinal metab. of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin and comparison with pravastatin)

RN 125638-71-3 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3-hydroxy-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

39

REFERENCE(S):

- (1) Benet, L; J Control Rel 1996, V39, P139 CAPLUS
- (3) Dimitroulakos, J; Nat Med 1996, V2, P326 CAPLUS
- (4) Estabrook, R; Methods Enzymol 1978, V52, P212 CAPLUS
- (5) Everett, D; Drug Metab Dispos 1991, V19, P740 CAPLUS
- (6) Flint, O; Toxicol Appl Pharmacol 1997, V145, P99 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2001 ACS

1999-587216 CAPLUS

DOCUMENT NUMBER: 131:346095

TITLE:

Grapefruit juice increases serum concentrations of

atorvastatin and has no effect on pravastatin

AUTHOR(S): Lilja, Jari J.; Kivistö, Kari T.; Neuvonen, Pertti J.  
CORPORATE SOURCE: Department of Clinical Pharmacology, University of  
Helsinki and Helsinki University Central Hospital,  
Helsinki, FIN-00290, Finland

SOURCE: Clin. Pharmacol. Ther. (St. Louis) (1999), 66(2)

118-127

CODEN: CLPTAT; ISSN: 0009-9236

PUBLISHER: Mosby, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

**AB** Background: Grapefruit juice greatly increases the bioavailability of lovastatin and simvastatin. We studied the effect of grapefruit juice on the pharmacokinetics of atorvastatin and pravastatin. Methods: Two randomized, two-phase crossover studies were performed; study I with atorvastatin in 12 healthy volunteers and study II with pravastatin in 11 healthy volunteers. In both studies, volunteers took 200 mL double-strength grapefruit juice or water three times a day for 2 days. On day 3, each subject ingested a single 40 mg dose of atorvastatin (study I) or pravastatin (study II) with either 200 mL grape-fruit juice or water, and an addnl. 200 mL was ingested 1/2 h and 1 1/2 h later. In addn., subjects took 200 mL grapefruit juice or water three times a day on days 4 and 5 in study I. In study I, serum concns. of atorvastatin acid, atorvastatin lactone, 2-hydroxyatorvastatin acid, 2-hydroxyatorvastatin lactone, and active and total 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors were measured up to 72 h. In study II, pravastatin, pravastatin lactone, and active and total HMG-CoA reductase inhibitors were measured up to 24 h. Results: Grapefruit juice increased the area under the serum concn.-time curve of atorvastatin acid from time zero to 72 h [AUC(0-72)] 2.5-fold ( $P < .01$ ), whereas the peak serum concn. (Cmax) was not significantly changed. The time of the peak concn. (tmax) and the elimination half-life (t<sub>1/2</sub>) of atorvastatin acid were increased ( $P < .01$ ). The AUC(0-72) of atorvastatin lactone was increased 3.3-fold ( $P < .01$ ) and the Cmax 2.6-fold ( $P < .01$ ) by grapefruit juice, and the tmax and t<sub>1/2</sub> were also increased ( $P < .05$ ). Grapefruit juice decreased the Cmax ( $P < .001$ ) and AUC(0-72) ( $P < .001$ ) of 2-hydroxyatorvastatin acid and increased its tmax and t<sub>1/2</sub> ( $P < .01$ ). Grapefruit juice also decreased the Cmax ( $P < .001$ ) and AUC(0-72) ( $P < .05$ ) of 2-hydroxyatorvastatin lactone. The AUC(0-72) values of active and total HMG-CoA reductase inhibitors were increased 1.3-fold ( $P < .05$ ) and 1.5-fold ( $P < .01$ ), resp., by grapefruit juice. In study II, the only significant change obsd. in the pharmacokinetics of pravastatin was prolongation of the tmax of active HMG-CoA reductase inhibitors by grapefruit juice ( $P < .05$ ). Conclusions: Grapefruit juice significantly increased serum concns. of atorvastatin acid, atorvastatin lactone, and active and total HMG-CoA reductase

inhibitors, probably by decreasing CYP3A4-mediated first-pass metab. of atorvastatin in the small intestine. On the other hand, grapefruit juice had no effect on the pharmacokinetics of pravastatin. Concomitant use of atorvastatin and at least large amts. of grapefruit juice should be avoided, or the dose of atorvastatin should be reduced accordingly.

IT 85956-22-5, Pravastatin lactone


RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(grapefruit juice increases serum concns. of atorvastatin and has no effect on pravastatin)

RN 85956-22-5 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3-hydroxy-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

24

REFERENCE(S):

- (2) Bailey, D; Br J Clin Pharmacol 1995, V40, P135  
CAPLUS
- (3) Bailey, D; Clin Pharmacol Ther 1993, V54, P589  
CAPLUS
- (4) Bailey, D; Clin Pharmacol Ther 1993, V53, P637  
CAPLUS
- (7) Haria, M; Drugs 1997, V53, P299 CAPLUS
- (9) Jacobsen, W; Drug Metab Dispos 1999, V27, P173  
CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:316101 CAPLUS

DOCUMENT NUMBER: 122:263678

TITLE: Synthesis of hydroxymethylglutaryl-CoA reductase inhibitors

INVENTOR(S): Carta, Giorgio; Conder, Michael J.; Gainer, John Lloyd; Stieberg, Robert W.; Vinci, Victor A.; Weber, Timothy Wallace

PATENT ASSIGNEE(S): Merck and Co., Inc., USA; University of Virginia Alumni Patents Foundation

SOURCE: PCT Int. Appl., 16 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9426920	A1	19941124	WO 1994-US5019	19940506
W: AU, BB, BG, BR, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5420024	A	19950530	US 1993-60847	19930511
CA 2161788	AA	19941124	CA 1994-2161788	19940506
AU 9469072	A1	19941212	AU 1994-69072	19940506
AU 673268	B2	19961031		
EP 698111	A1	19960228	EP 1994-917312	19940506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08510128	T2	19961029	JP 1994-525564	19940506
PRIORITY APPLN. INFO.:			US 1993-60847	19930511
			WO 1994-US5019	19940506

OTHER SOURCE(S): MARPAT 122:263678

GI



AB    HMG-CoA reductase inhibitors of formula (I) are formed by esterification employing an immobilized lipase in a nonaq. org. solvent. Thus, lovastatin diol lactone was incubated with nylon-immobilized lipase type VII from *Candida cylindracea* and 2-methylbutyric acid in a solvent of 1:1 CHCl<sub>3</sub>-hexane and shaken at room temp. Lovastatin formation occurred at a rate of 3.2 .times. 10<sup>-5</sup> mol/h-g lipase.

IT    159345-93-4, Pravastatin diol lactone


RL: BPR (Biological process); RCT (Reactant); BIOL (Biological study);  
PROC (Process)

(synthesis of hydroxymethylglutaryl-CoA reductase inhibitors with lipase)

RN    159345-93-4 CAPLUS

CN    2H-Pyran-2-one, 6-[2-(1,2,6,7,8,8a-hexahydro-6,8-dihydroxy-2-methyl-1-naphthalenyl)ethyl]tetrahydro-4-hydroxy-, [1S-[1.alpha.(2S\*,4S\*),2.alpha.,6.alpha.,8.beta.,8a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1994:68838 CAPLUS  
 DOCUMENT NUMBER: 120:68838  
 TITLE: Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone  
 AUTHOR(S): Ziegler, Kornelia; Hummelsiep, Silke  
 CORPORATE SOURCE: Institut fuer Pharmakologie und Toxikologie der Justus-Liebig Universitaet, Frankfurterstr. 107, Giessen, 35392, Germany  
 SOURCE: Biochim. Biophys. Acta (1993), 1153(1), 23-33  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Pravastatin and pravastatin-lactone are not taken up into extrahepatic cells such as fibroblasts, or hepatoma cells such as AS-30D ascites hepatoma cells or FAO cells. In contrast, pravastatin is taken up into isolated rat hepatocytes by a carrier mediated, saturable, temp.-dependent and energy-dependent mechanism. The kinetic parameters for the saturable uptake are  $K_m$  27 .mu.M,  $V_{max}$  537 pmol/mg per min. The permeability coeffs. were detd. to be 9.829.cntdot.10<sup>-7</sup> cm/s at 4.degree.C, 1.76.cntdot.10<sup>-6</sup> cm/s at 7.degree.C, 3.85.cntdot.10<sup>-6</sup> cm/s at 17.degree.C and 5.82.cntdot.10<sup>-6</sup> cm/s at 37.degree.C. The activation energy is 60 kJ/mol for 100 .mu.M pravastatin at 37.degree.C. The Q10 values are between 1.7 and 2.8. In the presence of metabolic inhibitors and in the absence of oxygen, transport is inhibited. Uptake of pravastatin is not dependent on an extracellular to intracellular sodium-gradient. Replacement of chloride by sulfate, nitrate, gluconate or thiocyanate significantly inhibits the uptake of pravastatin. Uptake is competitively inhibited by cholate and taurocholate in the presence and absence of sodium. Pravastatin, however, competitively inhibits the uptake of cholate and taurocholate only in the absence of sodium. In addn., pravastatin-lactone enters liver cells via an energy-dependent, carrier-mediated uptake system. For the saturable energy-dependent part of the hepatocellular uptake a  $K_m$  value of 9 .mu.M and a  $V_{max}$  value of 621 pmol/mg per min was detd. The permeability coeff. of pravastatin-lactone uptake is calcd. to be 5.41.cntdot.10<sup>-6</sup> cm/s at 37.degree.C. The uptake of pravastatin-lactone is competitively-noncompetitively inhibited by pravastatin and by lovastatin and vice versa. These results indicate that the hepatoselectivity of pravastatin is due to its carrier-mediated uptake into rat hepatocytes via a sodium-independent bile acid carrier. Pravastatin-lactone resembles pravastatin-sodium in its hepatoselectivity.

IT 143289-89-8, Pravastatin lactone

## RL: PROC (Process)



(carrier-mediated uptake of, by hepatocytes)

RN 143289-89-8 CAPLUS

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1983:516076 CAPLUS  
 DOCUMENT NUMBER: 99:116076  
 TITLE: Synergistic antichloesteremic activity of ML-236B derivatives  
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58090509	A2	19830530	JP 1981-188530	19811125
JP 01005571	B4	19890131		

GI



AB The carboxylic acids I or II (R1 and R2 = H or Me; R3 = H or OMe) (its salts, esters, and lactones) in combination with basic anion-exchange resins, which bind to bile acids, are synergistic anticholesteremics. Thus, 20 mg III Na salt [87098-76-8]/kg/day or 1 g cholestyramine [11041-12-6] given orally to dogs decreased blood cholesterol 35 and 33%, resp., but the combined administration decreased it 76% in 4 wk.

IT 85956-23-6


## RL: PROC (Process)

(isolation of, as anticholesteremic from Syncephalastrum nigricans)

RN 85956-23-6 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3-hydroxy-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	318.85	587.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-44.69	-44.69

STN INTERNATIONAL LOGOFF AT 18:21:20 ON 27 NOV 2001

Set Items Description  
-----  
? s (pravastatin or lovastatin or simvastatin or fluvastatin or atorvastatin or mevastatin) (20n) (silica? or grom? or krom? or licrosph?)  
4360 PRAVASTATIN  
4432 LOVASTATIN  
5360 SIMVASTATIN  
1411 FLUVASTATIN  
1451 ATORVASTATIN  
135 MEVASTATIN  
501317 SILICA?  
1944 GROM?  
932 KROM?  
9 LICROSPH?  
S1 16 (PRAVASTATIN OR LOVASTATIN OR SIMVASTATIN OR FLUVASTATIN OR ATORVASTATIN OR MEVASTATIN) (20N) (SILICA? OR GROM? OR KROM? OR LICROSPH?)

? rd  
...completed examining records  
S2 14 RD (unique items)

? t/3/1-14

2/3/1 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136058840 CA: 136(4)58840s PATENT  
Method of stabilizing medicinal compositions containing pravastatin  
INVENTOR(AUTHOR): Usui, Fusao; Yada, Shuichi; Kurihara, Kozo; Fukazawa,  
Toshio  
LOCATION: Japan,  
ASSIGNEE: Sankyo Company, Limited  
PATENT: PCT International ; WO 200197800 A1 DATE: 20011227  
APPLICATION: WO 2001JP5212 (20010619) \*JP 2000188983 (20000623)  
PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: Japanese CLASS: A61K-031/22A;  
A61K-047/02B; A61P-043/00B; A61P-003/06B DESIGNATED COUNTRIES: AU; BR; CA;  
CN; CO; CZ; HU; ID; IL; IN; KR; MX; NO; NZ; PL; RU; SG; SK; US; ZA  
DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;  
LU; MC; NL; PT; SE; TR

2/3/2 (Item 2 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136025124 CA: 136(2)25124h PATENT  
Pravastatin sodium pharmaceuticals containing compounds capable of  
binding carbon dioxide  
INVENTOR(AUTHOR): Pflaum, Zlatko; Milivojevic, Dusan; Rucman, Boris;  
Kogej, Stojan  
LOCATION: Slovenia,  
ASSIGNEE: Lek Pharmaceutical and Chemical Company D.D.  
PATENT: PCT International ; WO 200193859 A1 DATE: 20011213  
APPLICATION: WO 2000IB771 (20000609)  
PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/22A;  
A61K-031/366B; A61K-031/404B; A61K-047/02B DESIGNATED COUNTRIES: AE; AL;  
AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE;  
ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ;  
LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO;  
RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS;  
MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR;

NE; SN; TD; TG

2/3/3 (Item 3 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

135185491 CA: 135(13)185491h PATENT

Manufacture of pravastatin sodium tablets

INVENTOR(AUTHOR): Taniguchi, Toshiya; Terai, Takao; Ishizuka, Yasuhiro  
LOCATION: Japan,  
ASSIGNEE: Ohara Yakuhin Kogyo K. K.  
PATENT: Japan Kokai Tokkyo Koho ; JP 2001233766 A2 DATE: 20010828  
APPLICATION: JP 2000347383 (20000221) \*JP 200042927 (20000221)  
PAGES: 4 pp., Division of Jpn. Kokai Tokkyo Koho Appl. No. 00 42,927  
CODEN: JKXXAF LANGUAGE: Japanese CLASS: A61K-031/22A; A61K-009/20B;  
A61K-047/02B; A61K-047/12B; A61K-047/26B; A61K-047/36B; A61K-047/38B;  
A61P-003/06B

2/3/4 (Item 4 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

134114919 CA: 134(9)114919x PATENT

Microbial process for preparing pravastatin

INVENTOR(AUTHOR): Jekkel, Antonia; Ambrus, Gabor; Ilkoy, Eva; Horvath, Ildiko; Konya, Attila; Szabo, Istvan Mihaly; Nagy, Zsuzsanna; Horvath, Gyula; Mozes, Julia; Barta, Istvan; Somogyi, Gyorgy; Salat, Janos; Boros, Sandor

LOCATION: Hung.

ASSIGNEE: Gyogyszerekutato Intezet Kft.

PATENT: PCT International ; WO 0104340 A1 DATE: 20010118

APPLICATION: WO 2000HU66 (20000629) \*HU 999902352 (19990712)

PAGES: 29 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12P-017/06A;  
C12P-007/42B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;  
BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
MD; MG; MK; MN; MW; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ;  
TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;  
TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT;  
BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF;  
BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

2/3/5 (Item 5 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

133182996 CA: 133(13)182996z PATENT

Stable pravastatin sodium tablets

INVENTOR(AUTHOR): Tatebe, Satoshi

LOCATION: Japan,

PATENT: Japan Kokai Tokkyo Koho ; JP 2000229855 A2 DATE: 20000822

APPLICATION: JP 99117389 (19990426) \*JP 98366083 (19981207)

PAGES: 4 pp. CODEN: JKXXAF LANGUAGE: Japanese CLASS: A61K-031/235A;  
A61K-009/20B; A61P-003/06B; A61K-047/02B; A61K-047/24B; A61K-047/26B

2/3/6 (Item 6 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

117258210 CA: 117(26)258210F PATENT  
~~Purification of lovastatin and related compounds for pharmaceutical use~~  
INVENTOR(AUTHOR): Haytko, Peter N.; Wildman, Arthur S., Jr.  
LOCATION: USA  
ASSIGNEE: Merck and Co., Inc.  
PATENT: PCT International ; WO 9216276 A1 DATE: 921001  
APPLICATION: WO 92US1864 (920309) -US 668831 (910313)  
PAGES: 19 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: B01D-015/08A  
DESIGNATED COUNTRIES: CA; JP; US DESIGNATED REGIONAL: AT; BE; CH; DE; DK  
; ES; FR; GB; IT; LU; MC; NL; SE

2/3/7 (Item 1 from file: 34)  
DIALOG(R) File 34:SciSearch(R) Cited Ref Sci  
(c) 2002 Inst for Sci Info. All rts. reserv.

10360515 Genuine Article#: 518XJ No. References: 14  
Title: Effects of simvastatin on the phospholipid composition of  
high-density lipoproteins in patients with hypercholesterolemia  
Author(s): Ozerova IN; Paramonova IV; Olfer'ev AM; Akhmedzhanov NM;  
Aleksandrova MA; Perova NV  
Corporate Source: Russian Minist Hlth, State Res Ctr Prevent Med, Dept Metab  
Disorders, Moscow//Russia/  
Journal: BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2001, V132, N2 (AUG  
ISSN: 0007-4888 Publication date: 20010800  
Publisher: CONSULTANTS BUREAU, 233 SPRING ST, NEW YORK, NY 10013 USA  
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

2/3/8 (Item 2 from file: 34)  
DIALOG(R) File 34:SciSearch(R) Cited Ref Sci  
(c) 2002 Inst for Sci Info. All rts. reserv.

10018801 Genuine Article#: 476BC No. References: 5  
Title: Validated analysis of fluvastatin in a pharmaceutical capsule  
formulation and serum by capillary electrophoresis  
Author(s): Dogrukol-Ak D; Kircali K; Tuncel M; Aboul-Enein HY (REPRINT)  
Corporate Source: King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res  
, Pharmaceut Anal Lab, MBC 03, POB 3354/Riyadh 11211//Saudi Arabia/  
(REPRINT); King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res,  
Pharmaceut Anal Lab, MBC 03, Riyadh 11211//Saudi Arabia/; Univ  
Anadolu, Fac Pharm, Dept Analyt Chem, TR-26470 Tepebasi/Eskişehir/Turkey/  
Journal: BIOMEDICAL CHROMATOGRAPHY, 2001, V15, N6 (OCT), P389-392  
ISSN: 0269-3879 Publication date: 20011000  
Publisher: JOHN WILEY & SONS LTD, BAFFINS LANE CHICHESTER, W SUSSEX PO19  
1UD, ENGLAND  
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

2/3/9 (Item 3 from file: 34)  
DIALOG(R) File 34:SciSearch(R) Cited Ref Sci  
(c) 2002 Inst for Sci Info. All rts. reserv.

07669761 Genuine Article#: 194PK No. References: 6  
Title: Feasibility of lovastatin analysis by packed column supercritical  
fluid chromatography with ultraviolet detection  
Author(s): Strode JTB; Taylor LT (REPRINT) ; Howard AL; Ip D  
Corporate Source: VIRGINIA POLYTECH INST & STATE UNIV, COLL ARTS & SCI, DEPT  
CHEM, 107 DAVIDSON HALL/BLACKSBURG//VA/24061 (REPRINT); VIRGINIA  
POLYTECH INST & STATE UNIV, COLL ARTS & SCI, DEPT  
CHEM/BLACKSBURG//VA/24061; MERCK RES LABS, /W POINT//PA/19486  
Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, V20, N1-2

(JUN), P137-143

ISSN: 0731-7085 Publication date: 19990600

Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE,  
KIDLINGTON, OXFORD OX5 1GB, ENGLAND

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

2/3/10 (Item 4 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2002 Inst for Sci Info. All rts. reserv.

02813805 Genuine Article#: MF520 No. References: 4

Title: THE ISOLATION OF LOVASTATIN AND ITS DETERMINATION BY DENSITOMETRIC  
TLC AND BY HPLC

Author(s): KONFINO M; DELTCHEVA S; MINDJOVA K

Corporate Source: CHEM PHARMACEUT RES INST, 3 KL OHRIDSKI/BU-1156  
SOFIA//BULGARIA/

Journal: JPC-JOURNAL OF PLANAR CHROMATOGRAPHY-MODERN TLC, 1993, V6, N5 (SEP-OCT), P404-406

ISSN: 0933-4173

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

2/3/11 (Item 5 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2002 Inst for Sci Info. All rts. reserv.

00997184 Genuine Article#: FM030 No. References: 31

Title: QUANTITATIVE STUDIES OF TRANSFER INVIVO OF LOW-DENSITY, SF-12-60,  
AND SF-60-400 LIPOPROTEINS BETWEEN PLASMA AND ARTERIAL INTIMA IN HUMANS

Author(s): SHAIKH M; WOOTTON R; NORDESTGAARD BG; BASKERVILLE P; LUMLEY JS;  
LAVILLE AE; QUINEY J; LEWIS B

Corporate Source: RIGSHOSP,DEPT CLIN CHEM,KK 3011,BLEGDAMSVEJ 9/DK-2100  
COPENHAGEN//DENMARK/; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT  
CHEM PATHOL & METAB DISORDERS/LONDON//ENGLAND/; HAMMERSMITH HOSP,DEPT  
MED PHYS/LONDON W12 OHS//ENGLAND/; ST BARTHOLOMEWS HOSP,DEPT  
SURG/LONDON EC1A 7BE//ENGLAND/; ST THOMAS HOSP,RAYNE INST/LONDON SE1  
7EH//ENGLAND/

Journal: ARTERIOSCLEROSIS AND THROMBOSIS, 1991, V11, N3, P569-577

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

2/3/12 (Item 1 from file: 305)

DIALOG(R)File 305:Analytical Abstracts

(c) 2002 Royal Soc Chemistry. All rts. reserv.

340881 AA Accession No.: 64-24-G-10156 DOC. TYPE: Journal

Validated analysis of fluvastatin in a pharmaceutical formulation and serum  
by capillary electrophoresis.

AUTHOR: Dogrukol-Ak, D. ; Kircali, K. ; Tuncel, M. ; Aboul-Enein, H. Y.\*

CORPORATE SOURCE: enein@kfshrc.edu.sa, Pharm. Anal. Lab., Biol. and Med.  
Res. Dept., King Faisal Specialist Hospital and Res. Centre, Riyadh  
11211, Saudi Arabia

JOURNAL: Biomed. Chromatogr., (Biomedical Chromatography), Volume: 15,  
Issue: 6, Page(s): 389-392

CODEN: BICHE2 ISSN: 0269-3879

PUBLICATION DATE: Oct 2001 (20011000) LANGUAGE: English

2/3/13 (Item 2 from file: 305)

DIALOG(R)File 305:Analytical Abstracts

(c) 2002 Royal Soc Chemistry. All rts. reserv.

319027 AA Accession No.: 63-02-G-10163 DOC. TYPE: Journal  
Determination of lovastatin in human plasma by GC-MS.  
AUTHOR: Zheng, W. H. ; Cai, K. H. ; Wu, Y. L.  
CORPORATE SOURCE: Mol. Med. Res. Centre, Sun Yat-sen Univ. Sci., Guangzhou  
510089, China  
JOURNAL: Fenxi Ceshi Xuebao, (Fenxi Ceshi Xuebao), Volume: 19, Issue: 4,  
Page(s): 69-70  
CODEN: FCEXES ISSN: 1004-4957  
PUBLICATION DATE: Jul 2000 (20000700) LANGUAGE: Chinese

2/3/14 (Item 3 from file: 305)  
DIALOG(R)File 305:Analytical Abstracts  
(c) 2002 Royal Soc Chemistry. All rts. reserv.

305143 AA Accession No.: 62-08-G-10249 DOC. TYPE: Journal  
Analysis method and pharmacokinetic studies of simvastatin in plasma.  
AUTHOR: Cai, K. H. ; Zheng, W. H. ; Zhou, Y. ; Lin, G. Y. ; Zhao, X. L.  
CORPORATE SOURCE: Mol. Med. Res. Centre, Dept. Clinical Pharmacol., Sun Yat  
Sen Univ. Sci., Guangzhou 510089, China  
JOURNAL: Fenxi Huaxue, (Fenxi Huaxue), Volume: 27, Issue: 11, Page(s):  
1254-1257  
CODEN: FHHHDT ISSN: 0253-3820  
PUBLICATION DATE: 20 Nov 1999 (19991120) LANGUAGE: Chinese  
?

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS  
AN 1994:527684 CAPLUS  
DN 121:127684  
TI Challenges and frustrations in the separation and analysis of chiral agrochemicals  
AU Massey, Peter R.; Tandy, Michael J  
CS Prod. Characterization Group, Zeneca Agrochem., Bracknell/Berks, UK  
SO Chirality (1994), 6(2), 63-71  
CODEN: CHRLEP; ISSN: 0899-0042  
DT Journal; General Review  
LA English  
AB A review with 16 refs. of the development of chiral HPLC methods and isolation techniques within Zeneca Argochem. (formerly ICI Agrochem.). The use of low temp. to improve chiral sepn. has been successfully applied to prodn. anal., but although useful for some compds. it is regrettably not a universal panacea for all poor sepn. The need to isolate small quantities of individual enantiomers from new compds. for research evaluation has led the authors to devise a more universal and cheap chiral stationary phase (CSP) for Preparative-LC. Joint academic research produced a CSP based on tartaric acid which was made com. available and it was gratifying to find it was the only phase able to resolve a novel insecticide. However, as new CSPs emerged almost every mo, the authors' attention turned to using a universal chiral detector for anal., rather than via sepn. of individual enantiomers. Diode laser-based polarimeters offered the opportunity of cheap, sensitive chiroptical detectors for HPLC and the ability to move away from chiral columns in both research and prodn. anal. Jointly sponsored research with a university has successfully explored the versatility of chiroptical detectors in agrochem. and food anal. Comparison of chiral SFC with chiral HPLC and an extensive evaluation of established and research agrochem. on a wide range of com. CSPs have led to a revised method development strategy. Current work with high load **displacement chiral chromatog.** will be described as a potential means of isolating pure enantiomers from racemates.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS  
AN 1993:187112 CAPLUS  
DN 118:187112  
TI The use of **displacement chromatography** to alter retention and enantioselectivity on a human serum albumin-based HPLC chiral stationary phase: A mini-review  
AU Noctor, Terence A. G.; Wainer, Irving W.  
CS Dep. Oncol., McGill Univ., Montreal, PQ, H3G 1Y6, Can.  
SO J. Liq. Chromatogr. (1993), 16(4), 783-800  
CODEN: JLCHD8; ISSN: 0148-3919  
DT Journal; General Review  
LA English  
AB A review, with 27 refs., discussing the control of chromatog. retention ( $k'$ ) and enantioselectivity ( $\alpha$ ) on a human serum albumin-based HPLC chiral stationary phase which utilizes the binding characteristics of the protein.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS  
AN 1989:6120 CAPLUS  
DN 110:6120  
TI Fractionation of proteins at high capacity and high resolution by displacement chromatography  
AU Torres, Anthony R.; Peterson, Elbert A.  
CS Bio-Fract., Logan, UT, 84321, USA  
SO Sep. Biotechnol., [Pap. Int. Conf.] (1987), 176-84. Editor(s): Verrall, Michael S.; Hudson, Michael J. Publisher: Horwood, Chichester, UK.

CODEN: 56JPAR  
DT Conference; General Review  
LA English  
AB A review with 25 refs. on **displacement chromatog.** in biotechnol. Since biotechnol. has entered a new era with the ability to produce eukaryotic proteins in microorganisms or cell culture, high capacity and high resoln. purifications systems are needed to maximize the recovery of these protein products. **Displacement chromatog.** offers much higher capacities with improved resoln. over std. elution methods if proper spacing displacers can be found. Carboxymethyldextrans with varying carboxyl group incorporation behave as high resoln. spacing displacers on cellulosic and **HPLC** anion-exchangers. Other polymers, both natural or man-made may function as spacing displacers providing they can be produced with intermediate column affinities to the proteins being sepd.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS  
AN 1985:515117 CAPLUS  
DN 103:115117  
TI Displacement chromatography: yesterday, today and tomorrow  
AU Horvath, Csaba  
CS Dep. Chem. Eng., Yale Univ., New Haven, CT, 06520, USA  
SO J. Chromatogr. Libr. (1985), 32(Sci. Chromatogr.), 179-203  
CODEN: JCLIDR  
DT Journal; General Review  
LA English  
AB A review with 59 refs. The theory and recent developments in high-performance **displacement chromatog.**, esp. with regard to **HPLC**, are discussed.